Maxygen, Inc. (NASDAQ:MAXY)

CAPS Rating: 4 out of 5

A biotechnology company committed to the discovery and development of improved next-generation protein pharmaceuticals for the treatment of disease and serious medical conditions.

Recs

0
Player Avatar DoctorJA (< 20) Submitted: 2/1/2007 3:21:30 PM : Outperform Start Price: $9.02 MAXY Score: -32.16

Maxygen is one of the few remaining biotechs from the

Featured Broker Partners


Advertisement